| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18829515 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 105 journal articles in the PubMed database | Email to a friend | | |
| Hirsch FR, Varella-Garcia M, Dziadziuszko R, et al.
Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer. [Journal Article]
Clin Cancer Res 2008 Oct 1; 14(19):6317-23.
Abstract | Full Citation | Find Related Articles | | Herbst RS, Prager D, Hermann R, et al.
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. [Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Clin Oncol 2005 Sep 1; 23(25):5892-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Eberhard DA, Johnson BE, Amler LC, et al.
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. [Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Clin Oncol 2005 Sep 1; 23(25):5900-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Hirsch FR, Herbst RS, Olsen C, et al.
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. [Journal Article, Research Support, N.I.H., Extramural]
J Clin Oncol 2008 Jul 10; 26(20):3351-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Felip E, Rojo F, Reck M, et al.
A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. [Journal Article]
Clin Cancer Res 2008 Jun 15; 14(12):3867-74.
Abstract | Full Citation | | Ahn MJ, Park BB, Ahn JS, et al.
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? [Journal Article]
Clin Cancer Res 2008 Jun 15; 14(12):3860-6.
Abstract | Full Citation | | Zhu CQ, da Cunha Santos G, Ding K, et al.
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. [JOURNAL ARTICLE]
J Clin Oncol 2008 Jul 28.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Cappuzzo F, Ligorio C, Jänne PA, et al.
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. [Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
J Clin Oncol 2007 Jun 1; 25(16):2248-55.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Cappuzzo F, Ligorio C, Toschi L, et al.
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). [Journal Article, Research Support, Non-U.S. Gov't]
J Thorac Oncol 2007 May; 2(5):423-9.
Abstract | Full Citation | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
